Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

DNA polymerase inhibitor

DRUG CLASS:

DNA polymerase inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

cytarabine/daunorubicin liposomal formulation (19)

liposomal cytarabine (0)

cytarabine/daunorubicin liposomal formulation (19)

liposomal cytarabine (0)

›

No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: A1 - Approval cytarabine / daunorubicin liposomal formulation Sensitive : A1	cytarabine/daunorubicin liposomal formulation Sensitive: A1 - Approval cytarabine / daunorubicin liposomal formulation Sensitive : A1
SF3B1 mutation	Acute Myelogenous Leukemia	SF3B1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
CBL mutation	Acute Myelogenous Leukemia	CBL mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3
CEBPA mutation	Acute Myelogenous Leukemia	CEBPA mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
PHF6 mutation	Acute Myelogenous Leukemia	PHF6 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
STAG2 mutation	Acute Myelogenous Leukemia	STAG2 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
U2AF1 mutation	Acute Myelogenous Leukemia	U2AF1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3
TET2 mutation	Acute Myelogenous Leukemia	TET2 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3